Market Overview

Here's Why Prima BioMed Is Up 15%


Shares of Prima BioMed Ltd (ADR) (NASDAQ: PBMD), an Australia-based biotechnology company that is engaged in research, development and commercialization of licensed medical biotechnology, surged higher by more than 20 percent early Thursday morning.

Prima BioMed announced it has entered into an agreement with Sydys Corporation in which Sydys will license Prima's CVac immuno-oncology program (including manufacturing protocols, clinical data, patents and know-how) and also oversees its future development.

Pirma BioMed will also receive a 9.9 percent stake in Sydys at the closing of the deal in consideration for the assets being transferred. In addition, if CVac is successfully commercializes, Prima could receive a payment of up to A$400 million, or approximately $293 million.

Marc  Voigt,  Prima's  CEO,  commented, "Following  extensive discussions  with a umber of third parties, we have reached what we consider to be an entrepreneurial solution which we believe best positions CVac for clinical success and, hopefully, commercialization. Importantly, this partnership continues the CVac program development without further resource commitment from Primae, while providing the potential for considerable future milestone and royalty payments over time. The ongoing development will be contingent on further successful capital raising for subsequent trials but we are confident that the Sydys team has the ability and connections in the US to undertake this program."

Shares traded recently at $1.09, up 15.8 percent.


Related Articles (PBMD)

View Comments and Join the Discussion!

Posted-In: biotechnology biotechnology stocks Marc Voigt Prima BiomedBiotech News Movers General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at